PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
32.68%
Some net income increase while TRAW is negative at -326.82%. John Neff would see a short-term edge over the struggling competitor.
80.19%
Some D&A expansion while TRAW is negative at -4.00%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-398.37%
Negative yoy deferred tax while TRAW stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
30.65%
Less SBC growth vs. TRAW's 168.23%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
27.89%
Less working capital growth vs. TRAW's 108.14%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.29%
Both negative yoy AP, with TRAW at -154.11%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
66.06%
Growth well above TRAW's 107.79%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
30.65%
Growth of 30.65% while TRAW is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
-19.98%
Negative yoy CFO while TRAW is 9.15%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-32.37%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-271.58%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
69.11%
Debt repayment growth of 69.11% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-69.14%
Both yoy lines negative, with TRAW at -39.19%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.